21 completed. 21 Phase 2, 3 Phase 3, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 21 | Completed 21 |
| Phase 3 | 3 | Completed 3 |
| Phase 1 | 1 | Completed 1 |
Follow Anorexia: new trials by email Literature Review of Anorexia trials Research Report on Anorexia
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Effect of GLP-1 Analogue ROSE-010 on Appetite in Overweight and Obese Subjects ROSE-010 99 mcg, Placebo, ROSE-010 150 mcg - Obesity; Overweight | Phase 2 | Completed | Rose Pharma Inc | 40 | 2024-09-26 | 2026-06-01 |
| Study of the Efficacy and Safety of Ponsegromab in Patients With Cancer, Cachexia and Elevated GDF-15 ponsegromab, Placebo for ponsegromab - Non-small Cell Lung Cancer, Pancreatic Cancer | Phase 2 | Completed | Pfizer | 187 | 2022-11-21 | 2026-06-03 |
| Determination of In-vivo Plasma AA Appearance From Plant Protein Fibre Products Net peripheral AA appearance following ingestion of 3 selected PPF products compared to whey - Aging, Undernutrition | Phase 2 | Completed | University College Dublin | 9 | 2022-03-14 | 2022-09-26 |
| Evaluation of Psilocybin in Anorexia Nervosa: Safety and Efficacy Psilocybin - Anorexia Nervosa | Phase 2 | Completed | University of California, San Diego | 16 | 2021-05-01 | 2022-07-25 |
| Comparison Between Mirtazapine and Megestrol for the Control of Anorexia-cachexia in Cancer Patients in Palliative Care. Mirtazapine, Megestrol - Cachexia; Cancer, Anorexia | Phase 2 | Completed | University of Sao Paulo | 52 | 2019-03-26 | 2023-07-07 |
| Phase 2 Pilot Study to Evaluate the Safety and Efficacy of RM-131 Administered to Females With Anorexia Nervosa RM-131, Placebo - Anorexia Nervosa | Phase 2 | Completed | Motus Therapeutics, Inc. | 20 | 2012-11-01 | 2016-09-23 |
| A Clinical Study of Trazodone Hydrochloride Prolonged-Release Tablets for Treatment of Depression Trazodone, Placebo - Depression | Phase 2 / Phase 3 | Completed | Lee's Pharmaceutical Limited | 382 | 2011-11-01 | 2014-10-16 |
| DaHuang GangTsao Tang to Improve the Appetite Loss Condition of Cancer Patients DaHuang GanTsao Tang - Non-organic Loss of Appetite | Phase 2 | Completed | Changhua Christian Hospital | 4 | 2011-03-01 | 2020-02-17 |
| Olanzapine for the Treatment of Appetite Loss in Amyotrophic Lateral Sclerosis (ALS) Olanzapine - Amyotrophic Lateral Sclerosis (ALS) | Phase 2 / Phase 3 | Completed | Charite University, Berlin, Germany | 40 | 2011-03-01 | 2024-02-14 |
| Omega-3 Fatty Acids as Adjunct Treatment for Major Depressive Disorder Low Dose Fish Oil, High Dose Fish Oil - Major Depressive Disorder | Phase 2 / Phase 3 | Completed | University of Cincinnati | 20 | 2007-08-01 | 2016-05-27 |
| Regimen for the Treatment of Cachexia in Subjects With NSCLC VT-122 low dose, VT-122 high dose - Cachexia | Phase 2 | Completed | Vicus Therapeutics | 37 | 2007-01-01 | 2013-01-30 |
| Palonosetron for Prevention of Biochemotherapy Induced Nausea and Vomiting Palonosetron - Melanoma | Phase 1 / Phase 2 | Completed | M.D. Anderson Cancer Center | 30 | 2006-11-01 | 2012-05-04 |
| The Effects of Thalidomide on Symptom Clusters Thalidomide, Placebo - Advanced Cancers | Phase 2 | Completed | M.D. Anderson Cancer Center | 32 | 2006-09-01 | 2013-02-04 |
| Orexigenic Therapy With Delta-9-tetrahydrocannabinol in Advanced Cancer Patients With Chemosensory Abnormalities - a Pilot Study Marinol (Dronabinol), Placebo - Cancer, Anorexia | Phase 2 | Completed | Alberta Health services | 80 | 2006-08-01 | 2010-02-09 |
| Safety and Efficacy of APD356 in the Treatment of Obesity APD356 - Obesity | Phase 2 | Completed | Eisai Inc. | 400 | 2005-06-01 | 2019-09-12 |
| Safety and Efficacy of RC-1291 HCl in Patients With Cancer Related Anorexia and Weight Loss RC-1291 HCl - Cancer Cachexia | Phase 2 | Completed | Helsinn Therapeutics (U.S.), Inc | 80 | 2005-06-01 | 2013-09-02 |
| Evaluate Weight Gain Using 2 Different Formulations of Megestrol Acetate Oral Suspension for AIDS-related Weight Loss Megestrol acetate oral suspension nanocrystal dispersion 115 mg/mL, Megestrol acetate oral suspension 40 mg/mL - HIV Infections, Cachexia | Phase 2 | Completed | Endo USA Inc., a Keenova Therapeutics Company | 63 | 2004-12-01 | 2017-10-05 |
| Safety and Efficacy of APD356 in the Treatment of Obesity APD356 - Obesity | Phase 2 | Completed | Eisai Inc. | 400 | 2004-12-01 | 2019-09-12 |
| Comparing the Effectiveness of Three Types of Therapy for the Treatment of Anorexia Nervosa in Adolescents Family therapy (FT), Individual therapy (IT) - Eating Disorders | Phase 2 | Completed | University of Chicago | 121 | 2004-04-01 | 2016-06-20 |
| A Study of the Safety and Effectiveness of Infliximab (Remicade) in Patients With Pancreatic Cancer Related Cachexia Infliximab; Gemcitabine - Cachexia, Pancreatic Neoplasms | Phase 2 | Completed | Centocor, Inc. | 73 | 2003-04-01 | 2011-05-17 |
Showing 20 of 21. Sign in to see all of them.
Cachexia (8) · Weight Loss (5) · Anorexia Nervosa (3) · Fatigue (3) · Feeding and Eating Disorders (3) · Neoplasms (3) · Obesity (3) · Overweight (3) · HIV Infections (2) · Malnutrition (2) · Pancreatic Neoplasms (2) · Acquired Immunodeficiency Syndrome (1) · Amyotrophic Lateral Sclerosis (1) · Anemia (1)
Pathological Conditions, Signs and Symptoms (21) · Signs and Symptoms (21) · Signs and Symptoms, Digestive (21) · Body Weight (12) · Body Weight Changes (10) · Thinness (8) · Nutrition Disorders (6) · Nutritional and Metabolic Diseases (6) · Weight Loss (6) · Mental Disorders (3) · Neoplasms by Site (3) · Nervous System Diseases (3) · Overnutrition (3) · Blood-Borne Infections (2) · Communicable Diseases (2)
Megestrol Acetate (3) · lorcaserin (2) · Dronabinol (1) · Family Therapy (1) · Fish Oils (1) · Gemcitabine (1) · Infliximab (1) · Megestrol (1) · Mirtazapine (1) · Olanzapine (1) · Palonosetron (1) · Psilocybin (1) · Thalidomide (1) · Trazodone (1) · glucagon-like peptide (7-37), valyl(10)- (1)
Eisai Inc. (2) · M.D. Anderson Cancer Center (2) · Alberta Health services (1) · Bristol-Myers Squibb (1) · Centocor, Inc. (1) · Changhua Christian Hospital (1) · Charite University, Berlin, Germany (1) · Endo USA Inc., a Keenova Therapeutics Company (1) · Helsinn Therapeutics (U.S.), Inc (1) · Lee's Pharmaceutical Limited (1) · Motus Therapeutics, Inc. (1) · Pfizer (1) · Rose Pharma Inc (1) · University College Dublin (1) · University of California, San Diego (1)
United States (14) · Canada (2) · China (2) · India (2) · Taiwan (2) · Australia (1) · Brazil (1) · Bulgaria (1) · Germany (1) · Hungary (1) · Ireland (1) · Italy (1) · Japan (1) · Poland (1) · Slovakia (1)
Agop Y. Bedikian, MD (1) · Anne Klibanski, MD (1) · Benjamin LI, Ph.D. (1) · Daniel Le Grange, PhD (1) · Dominique Dardevet, Dr (1) · Eduardo Bruera, MD (1) · Giuseppe De Vito, Prof (1) · Ingrid H. de Kock, MD (1) · Jan Fourie, MD (1) · Katy Horner, Dr (1) · Nereida KC Lima, MD, PhD (1) · Richard A Guarino, MD (1)
PMID 18257397, PMID 19057523, PMID 21343383, PMID 25524795, PMID 29325236, PMID 37488291, PMID 38500292, PMID 38988455, PMID 39282907
2023 (1), R01MH070620 (1)